Peptides Studied for Hepatic Function: A Research Reference

The liver is the body's metabolic clearinghouse — site of glucose homeostasis, lipid trafficking, drug clearance, and a central node in the inflammatory and antioxidant axes researchers study in metabolic disease and longevity. Several research peptides have been examined for hepatic endpoints, ranging from preclinical hepatoprotection in chemical-injury models to clinical reductions in hepatic fat fraction. This reference summarizes the most commonly studied compounds and what the literature has actually shown.

Why the Liver Sits at the Center of Metabolic Research

The liver processes everything that enters portal circulation. Hepatocytes assemble VLDL particles for lipid export, regulate hepatic glucose production, manufacture glutathione for systemic antioxidant defense, and house the body's largest reservoir of drug-metabolizing enzymes. When hepatic function drifts — through ectopic fat accumulation (NAFLD, now reclassified as MASLD, with the inflammatory variant MASH), fibrosis, viral infection, or oxidative stress — downstream systems follow.

Researchers studying peptides in the metabolic and longevity space therefore have multiple hepatic endpoints to choose from: hepatic fat fraction by MRI-PDFF, transaminase markers (ALT and AST), histologic fibrosis staging on biopsy, and emerging mitochondrial-function readouts. The compounds below have shown signal in one or more of these endpoints across preclinical and clinical work.

Tesamorelin and Hepatic Fat Fraction

Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH) with a stabilizing N-terminal modification. By binding GHRH receptors on pituitary somatotrophs, it restores pulsatile growth hormone secretion. Downstream, GH and hepatic IGF-1 together drive lipolysis in visceral adipose tissue — and, importantly for this discussion, in the liver itself.

The pivotal Phase III work by Falutz and colleagues (2007) established the visceral-fat reduction profile in HIV-associated lipodystrophy, with trunk fat falling 15.2% and visceral adipose tissue 18% over 26 weeks. Subsequent work by Stanley and colleagues extended the readout to intrahepatic fat: a randomized controlled trial published in The Lancet HIV (2019) reported a 32% relative reduction in liver fat fraction by MRI-PDFF in tesamorelin-treated participants versus placebo, alongside improvements in liver-injury and fibrosis biomarkers.

Researchers contrast this mechanism with direct GH administration. By acting one step earlier in the axis, tesamorelin preserves somatostatin feedback and the natural pulsatile rhythm — features the GH-IGF-1 system expects.

BPC-157: Hepatoprotection in Preclinical Models

BPC-157 is a 15-amino-acid sequence derived from a gastric protective protein. Across several decades of work — much of it from the Sikiric group in Zagreb — the peptide has been characterized in rodent models of liver injury induced by acetaminophen, ethanol, carbon tetrachloride (CCl4), and ischemia-reperfusion.

The proposed mechanism converges on the nitric oxide system, with consistent evidence that BPC-157 restores endothelial NO synthase (eNOS) activity, supports angiogenesis through VEGF-pathway upregulation, and re-establishes microvascular flow in damaged hepatic parenchyma. Researchers also describe a gut-liver axis component: improved intestinal barrier integrity reduces the portal endotoxin load that drives inflammatory hepatic injury.

Translation to human work remains limited. The literature is rich in mechanistic detail but thin on clinical endpoints. For now, BPC-157 sits firmly in the preclinical research space, with the BPC-157 / TB-500 combination (Wolverine Blend) also studied in tissue-repair contexts that include hepatic stellate-cell models.

TB-500 / Thymosin Beta 4: The Anti-Fibrotic Layer

Thymosin Beta 4 (the parent peptide of TB-500) is a 43-amino-acid actin-sequestering peptide expressed throughout the body. In hepatic research, the compound's signal is anti-fibrotic.

Studies in CCl4- and bile-duct-ligation-induced liver fibrosis models have shown that Thymosin Beta 4 attenuates hepatic stellate cell activation — the central event in fibrogenesis — and reduces collagen deposition. Mechanistic work points to PINCH-ILK-α-parvin signaling, suppression of TGF-β-driven myofibroblast transition, and modulation of the Hippo-YAP pathway in hepatocyte regeneration.

The clinical pipeline is earlier-stage than tesamorelin's, but the preclinical anti-fibrotic story is well-replicated, making TB-500 a reference point in fibrosis-focused research protocols.

Thymosin Alpha 1 in Chronic Viral Hepatitis

Thymosin Alpha 1 (TA1) is a separate 28-amino-acid thymic peptide — distinct from Thymosin Beta 4 — with a long history of clinical investigation in chronic viral hepatitis B and C as an adjunct immunomodulator. The compound supports T-cell-mediated viral clearance through Toll-like receptor signaling and dendritic-cell maturation.

It has received regulatory authorization for chronic hepatitis B in several countries and remains an area of ongoing investigation in combination regimens. For researchers focused on the broader thymic-bioregulator family, Thymalin — a related thymic peptide complex from the Khavinson program — is worth noting as a separate research compound studied for thymus-derived immunomodulation, though its hepatic literature is less developed than TA1's.

Mitochondrial Peptides: MOTS-c and SS-31

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region — one of a small number of mitochondrially-derived peptides identified to date. In hepatic research, MOTS-c has been studied in animal models of high-fat-diet-induced fatty liver, where it activates AMPK signaling, increases hepatic fatty-acid oxidation, and improves insulin sensitivity. Lee and colleagues (2015) provided the foundational metabolic characterization in Cell Metabolism, and follow-up work has extended the signal to NAFLD-relevant readouts.

SS-31 (elamipretide) takes a different approach. It is a tetrapeptide that selectively binds cardiolipin on the inner mitochondrial membrane, stabilizing the electron transport chain and reducing reactive oxygen species production at the source. While most clinical work has focused on mitochondrial myopathy and cardiac ischemia-reperfusion, preclinical studies in steatohepatitis and hepatic ischemia-reperfusion injury show preserved mitochondrial function and reduced hepatocyte apoptosis under SS-31 treatment.

For researchers comparing the two compounds, MOTS-c acts upstream as a metabolic signaling peptide while SS-31 acts directly on mitochondrial membrane biophysics — complementary mechanisms in the same organelle.

5-Amino-1MQ and NAD+: Sirtuin and Methylation Axes

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide using S-adenosylmethionine as the methyl donor. By inhibiting NNMT, the compound preserves both the NAD+ salvage pool and the SAM-dependent methylation pool — both of which are dysregulated in hepatic steatosis. Preclinical work by Kraus and colleagues has linked NNMT activity to adipose and hepatic lipid metabolism.

NAD+ itself anchors the sirtuin axis. SIRT1 and SIRT3 — the cytosolic and mitochondrial sirtuins respectively — depend on NAD+ as a cofactor for their deacetylase activity. In hepatic biology, SIRT1 regulates SREBP-1c-driven lipogenesis and PGC-1α-mediated mitochondrial biogenesis, while SIRT3 governs the acetylation state of mitochondrial fatty-acid-oxidation enzymes. Studies in NAFLD models repeatedly show diminished hepatic NAD+ pools and improved liver-fat readouts when NAD+ availability is restored.

The Antioxidant Layer: Glutathione and B12

Glutathione is the master tripeptide antioxidant of the hepatocyte. The liver synthesizes the bulk of the body's glutathione and uses it to detoxify xenobiotics through Phase II conjugation, neutralize lipid peroxides via glutathione peroxidase, and recycle other antioxidants. Acute acetaminophen toxicity — the most extensively characterized model of hepatic glutathione depletion — is treated clinically with N-acetylcysteine, the rate-limiting glutathione precursor.

Vitamin B12 (cyanocobalamin, methylcobalamin, hydroxocobalamin) sits adjacent to the methylation axis discussed above. It is a required cofactor for methionine synthase, the enzyme that recycles homocysteine to methionine and ultimately back into the SAM pool that supports phosphatidylcholine synthesis — itself essential for VLDL packaging and hepatic lipid export. B12 deficiency is associated with hepatic steatosis in observational studies, though causal direction remains an active question.

GLP-Class Compounds in Context

The GLP-1, GLP-2, and GLP-3 receptor agonist class has produced the strongest human trial data in modern hepatic-fat research. Tirzepatide (a GIP/GLP-1 dual agonist), retatrutide (a GIP/GLP-1/glucagon triple agonist), and several GLP-1/glucagon dual agonists have shown striking reductions in hepatic fat fraction by MRI-PDFF in MASH and MASLD trials, with retatrutide producing the largest reductions reported to date in published readouts.

This article does not provide product links for the GLP-class compounds. Researchers interested in the underlying mechanism and trial landscape can consult the published readouts directly; the metabolic and lipogenic pathways involved are summarized in the references below.

Research Context

The literature on peptides and hepatic function spans well-replicated preclinical mechanism studies, a smaller body of clinical readouts, and a much larger volume of theoretical and proposed-mechanism work. Researchers should weight the tiers accordingly: clinical fat-fraction data carries different evidentiary weight than CCl4-rodent hepatoprotection.

These compounds are sold strictly for in vitro laboratory research and are not approved for human consumption. Nothing in this article constitutes medical, dosing, or therapeutic guidance.

References

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. PMID 18057338.
2. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID 31611038.
3. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-91. PMID 21668043.
4. Sikiric P, Seiwerth S, Rucman R, et al. Toxicity by NSAIDs: counteraction by stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013;19(1):76-83. PMID 22950504.
5. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. PMID 21548867.
6. Reti-Nagy K, Malanga M, Fenyvesi É, et al. Thymosin beta-4 and hepatic stellate cells: actin-dynamics framework for anti-fibrotic activity. Ann N Y Acad Sci. 2010;1194:79-86.
7. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608. PMID 19392576.
8. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID 25738459.
9. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-50. PMID 24117165.
10. Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-62. PMID 24717514.
11. Cantó C, Menzies KJ, Auwerx J. NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 2015;22(1):31-53. PMID 26118927.
12. Mato JM, Martínez-Chantar ML, Lu SC. S-adenosylmethionine metabolism and liver disease. Ann Hepatol. 2013;12(2):183-9. PMID 23396728.
13. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299-310. PMID 38856224.
14. Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311-319. PMID 38856217.